Freeman Kevin D's Form 4/A amendment
AmendedGalectin Therapeutics Inc (GALT) · filed Dec 23, 2025
- Accession no.
- 0001133416-25-000080
- Filed
- Dec 23, 2025
- Trade date
- Dec 23, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
- Original filed
- Dec 23, 2025
This filing lists 1 non-derivative transaction. Open-market purchases total $19.5K. It was filed on the trade date.
This filing was later replaced by the amendment 0001133416-25-000081 (Dec 23, 2025). Trade tables on this site use the amended version.
This amendment replaces 0001133416-25-000075 (filed Dec 23, 2025).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Freeman Kevin DCIK 0001522478 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 23, 2025 | Common Stock | PPurchaseAcquired | +5,500 | $3.55 | +$19,525 | 55,269 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.